Schering AG Bolsters MS Pipeline With Acquisition Of Celera Research Program
This article was originally published in The Pink Sheet Daily
Celera’s cathepsin S inhibitor program includes CRA-028129, now in Phase I, for treatment of autoimmune diseases.
You may also be interested in...
Bayer has met the quota for percentage of shares needed to acquire Schering AG, the firm said June 19
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.
A Phase III trial will compare 40 mg/day glatiramer to the 20 mg/day approved dose.